Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” 5520), and the Veterans Equal Access Act (H.R. However, it is clear that there is momentum to give veterans access to cannabis. Yes, it has.

Law 62

Law Chronic Pain Conditions Legislation 62

Veriheal

SEPTEMBER 13, 2022

Grow rooms require ventilation, lights, environmental controls, and other optimal environmental conditions in order for cannabis plants to thrive. It also may be more convenient to grow cannabis at home if a consumer lives in a rural area or in a state that only has a limited number of accessible dispensaries.

Cultivation 109

Cultivation Data DEA Dispensary 109

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. Drug Enforcement Agency (DEA). This means that U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” This research—as with psilocybin, MDMA, ketamine, ibogaine etc.—is

Therapy 88

Therapy Clinical Trials DEA Microdosing 88

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA). Times (Nov.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

PrestoDoctor

FEBRUARY 6, 2023

The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. Oklahoma does not have a specific list of conditions to get a MMJ recommendation. Other states have a list of qualifying conditions that the patients must meet to get an MMJ. Will I Be On a List?

Marijuana 52

Marijuana Patients Conditions Access 52

CannaMD

SEPTEMBER 15, 2020

MORE DETAILS: On June 16, 2014, Florida became the 22nd state to legalize (at least partial) access to medical marijuana when Governor Rick Scott signed the Compassionate Medical Cannabis Act of 2014. SHORT ANSWER: Full-time and seasonal Florida residents who suffer from an eligible medical condition. ” Translation?

Law 126

Law Marijuana Patients Treatment 126

Veriheal

DECEMBER 1, 2020

Cannabis has shifted from being conceived as a drug choice of lazy people to becoming a potent, powerful medicine that helps with many different ailments and conditions. The DEA is Already Interfering. Way to go, DEA, on jumping the gun showing your true colors. The abbreviation stands for tetrahydrocannabinol.

THC 52

THC DEA Research and Development Cannabinoids 52

Canna Care Docs

SEPTEMBER 26, 2019

Powered by Sail, we are on a mission to solve the issue of cannabis access for patients. Evaluate patient for verification of a qualifying condition. We are expanding.Patients are seeking alternative solutions to their difficult and painful conditions. WE ARE SEEKING LICENSED MD OR ARPNs for our Hartford, CT clinic.

History 40

History DEA Therapy Patients 40

Cannabis Law Report

JANUARY 23, 2020

This is not least due to its exceptional cultivation conditions and central position within the Southeast Asian trading zone. This is not least due to its exceptional cultivation conditions and central position within the Southeast Asian trading zone. in the 1970. Healthcare expenditure 2018.

Research and Development 59

Research and Development Oil Cultivation DEA 59

Canna Law Blog

MARCH 21, 2022

To impose a hemp moratorium, a county must simply declare a state of emergency related to cannabis and notify the Oregon Department of Agriculture ( ODA ) of the declaration and request that the ODA deny issuance of grower licenses in order to alleviate the conditions giving rise to the declaration.

Hemp 75

Hemp DEA Conditions Agriculture 75

Canna Law Blog

JULY 14, 2023

You can access the letters here. But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. On July 5, 2023, the FDA and FTC jointly announced six cease and desist letters to alleged delta-8 product makers. You can read more about that issue here or here.

Packaging 74

Packaging Food Edibles THC 74

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . Promising clinical trial results have generated much interest in studying MDMA as a catalyst to therapy for PTSD and related conditions — and an increased demand for pharmaceutical-grade MDMA.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JULY 23, 2021

Drug Enforcement Agency (DEA) to the Alcohol and Tobacco Tax and Trade Bureau (TTB), the Bureau of Alcohol Tobacco Firearms and Explosives (ATF). It would transfer primary agency jurisdiction over cannabis from the DEA to the FDA, TTB, and ATF. of Health and Human Services to research the effects of cannabis on health conditions.

Research and Development 105

Research and Development DEA Programs State Laws 105

Veriheal

DECEMBER 27, 2022

Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

Research and Development 95

Research and Development Therapy Consumption DEA 95

NewsMunchies

MAY 20, 2021

Access to legally produced cannabis, lest your research get kicked as violating federal laws on controlled substances even if sold legally at your State’s level, was limited. This action by the DEA means researchers will be able to study marijuana from more than one grower. Rate this blog post.

DEA 98

DEA Chronic Pain Terpenes Packaging 98

Cannabis Law Report

JULY 9, 2021

Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval. Drug Enforcement Agency (“DEA”). Briefing is still under way, with the DEA’s responsive brief submitted on June 25, 2021, and the petitioners’ reply due July 16, 2021. AIMS Institute, PLLC.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

MAY 31, 2022

The only opportunity to currently participate would be through an active clinical trial or via an argument under the Right to Try Act of 2018 (an act which provides a pathway for patients with life-threatening diseases or conditions to access unapproved treatments). Emerging Non-Medical State-Regulated Path.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

SpeedWeed

AUGUST 19, 2021

In recent months, a synthetic compound derived from hemp called THC-O acetate—often referred to simply as THC-O (pronounced “THC oh”)—has quickly gained popularity among Americans who don’t have access to legal cannabis. . THC-O products are increasingly popular in states where consumers don’t have access to legal cannabis.

THC 52

THC Hemp Extraction Vaping 52

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JANUARY 13, 2022

1, Louisiana’s medical cannabis program allows patients to access smokable whole-plant flower marijuana. 1, out-of-state medical marijuana patients may access Arkansas’ program to purchase cannabis for up to 90 days. 1, Philadelphia employers cannot require applicants to be drug-tested for marijuana as a condition of employment.

Dispensary 52

Dispensary Law Concentrates Patients 52

PrestoDoctor

JANUARY 14, 2020

The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. The physician may review a list of qualifying conditions. Other states have a list of conditions that the patients must meet to get an MMJ. Oklahoma does not have a specific list of conditions to get an MMJ.

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

JANUARY 14, 2020

The physician will conduct an evaluation to determine if your medical condition can improve with marijuana use. The physician may review a list of qualifying conditions. Other states have a list of conditions that the patients must meet to get an MMJ. Oklahoma does not have a specific list of conditions to get an MMJ.

Marijuana 52

Marijuana Patients Conditions Programs 52

CannaMD

MAY 6, 2020

In practice, the chances of feds or the DEA sitting at the border waiting to catch someone – that’s just not happening. However, Americans for Safe Access reminds patients: The best law enforcement encounter is the encounter that never occurs. For more information, see: Safe Access: Becoming a Patient in Maine.

Hash 103

Hash Legalization Marijuana Concentrates 103

SpeedWeed

MARCH 18, 2021

Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. Wasn’t the DEA going to let others grow research-grade cannabis? It tested at only 9% THC. Research quality” cannabis sparked earlier controversy.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. Patients Are Not In This Alone.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

APRIL 14, 2022

Local governments may also impose zoning conditions on cannabis facilities, including but not limited to buffer zones, density conditions, hours of operation, odor control requirements, necessary operating permits, and storefront characteristics. pursuant to Drug Enforcement Agency (DEA) or state-level programs).

Environment 52

Environment Agriculture Compliance Compliance 52

MedicalJane

OCTOBER 5, 2017

Using cannabis as a medicine is not a new practice, and recent research shows that cannabis extracts may represent an efficacious and safe alternative for treatment of a wide range of conditions in women including dysmenorrhea, dysuria, hyperemesis gravidarum, and menopausal symptoms. ” – Dr. Russo.

Marijuana 65

Marijuana Treatment Extraction Medicine 65

Veriheal

AUGUST 31, 2020

However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. This can help change the way people look at the substance.

Research and Development 117

Research and Development Education Agriculture Patients 117

Canna Law Blog

NOVEMBER 6, 2021

Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. That power is typically delegated to the DEA. Psilocybin’s federal status as a Schedule I controlled substance is to blame.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

JULY 1, 2021

These designations indicate that psychedelics may represent substantial improvements over existing treatments for mental health conditions. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries. Chloe Reichel: Can you describe the primary goals of POPLAR?

Law 105

Law Research and Development Therapy DEA 105

Veriheal

AUGUST 19, 2022

” Cannabis Research Should Be Based on Real, Accessible Products. In February 2021, a lawsuit was filed against the DEA for prohibiting access for others aside from the University of Mississippi to cultivate cannabis for research purposes. Do researchers need access to consistent market-quality cannabis for research?

Hemp 52

Hemp DEA Access Cultivation 52

Canna Law Blog

MARCH 4, 2020

” Oftentimes, a healthcare provider may prescribe a drug off-label because there might not be an approved drug out there yet to treat the subject medical condition or because no other medication has worked yet for the patient. That access would be available under the auspices of having a chronic, untreatable mood disorder.

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

JUNE 1, 2021

A replay will be accessible by webcast until 11:59 PM ET on August 30, 2021 at: [link]. Drug Enforcement Administration (the “DEA”), the U.S. The Company will host a conference call and audio webcast with David Klein , CEO and Mike Lee , CFO at 10:00 AM Eastern Time on June 1, 2021. Webcast Information.

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

MAY 17, 2019

Seq (1970) and Drug Enforcement Administration’s (“DEA”) clutches, 2019 hemp production and sales exploded. A wildly popular nutritional supplement and food additive, oil based hemp derived products like CBD racked up $1.1 Farm Bill’s Impact and Rise of the FDA. Beyond removing plant cannabis sativa L. Budgeted at $6.1

Food 10

Food DEA Hemp CBD 10

Canna Law Blog

MARCH 4, 2020

” Oftentimes, a healthcare provider may prescribe a drug off-label because there might not be an approved drug out there yet to treat the subject medical condition or because no other medication has worked yet for the patient. That access would be available under the auspices of having a chronic, untreatable mood disorder.

Legalization 52

Legalization Therapy Chronic Pain DEA 52